

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
HNSA | Stockholm | SEK | Real-time | |
HNSAs | BATS Europe | SEK | Delayed | |
24H | Frankfurt | EUR | Delayed |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company’s lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Mats Peter Blom | 58 | 2019 | Independent Director |
Andreas Eggert | 56 | 2018 | Independent Director |
Anders Gersel Pedersen | 72 | 2018 | Independent Director |
Gunnar Tufveson | - | - | Chairman of European Medical Advisory Board in Transplantation |
Stanley Jordan | - | - | Chairman of US Medical Advisory Board in Transplantation |
Robert A. Montgomery | - | - | Member of US Medical Advisory Board in Transplantation |
Christophe Legendre | - | - | Member of European Medical Advisory Board in Transplantation |
Kathryn Wood | - | - | Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation |
Hilary M. Malone | 58 | 2021 | Independent Director |
Eva Nilsagard | 59 | 2019 | Independent Director |
Peter Nicklin | 60 | 2022 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review